Financial Comparison: Halozyme Therapeutics (NASDAQ:HALO) vs. Scinai Immunotherapeutics (NASDAQ:SCNI)

Halozyme Therapeutics (NASDAQ:HALO) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Halozyme Therapeutics and Scinai Immunotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0	4	5	0	2.56
Scinai Immunotherapeutics	0	0	0	0	N/A

Halozyme Therapeutics presently has a consensus price target of $60.44, suggesting a potential upside of 12.31%. Given Halozyme Therapeutics’ higher possible upside, equities research analysts clearly believe Halozyme Therapeutics is more favorable than Scinai Immunotherapeutics.

Risk and Volatility

Halozyme Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.

Earnings & Valuation

This table compares Halozyme Therapeutics and Scinai Immunotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$873.30 million	7.84	$281.59 million	$2.42	22.24
Scinai Immunotherapeutics	$284,000.00	6.13	-$6.50 million	($261.70)	-0.01

Halozyme Therapeutics has higher revenue and earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Halozyme Therapeutics and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	38.62%	195.80%	21.07%
Scinai Immunotherapeutics	N/A	N/A	-107.47%

Institutional and Insider Ownership

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Halozyme Therapeutics beats Scinai Immunotherapeutics on 11 of the 13 factors compared between the two stocks.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.